Govt loosens PBS rules for COVID-19 antiviral
An additional 160,000 Australians will have access to the COVID-19 antiviral nirmatrelvir–ritonavir under new PBS eligibility criteria. From 1 April, those aged 60-69 with mild-to-moderate…
Tag: Antiviral
COVID-19 antivirals: Doctors clash over PBS eligibility
Leading doctors have clashed over eligibility criteria for COVID-19 antivirals — specifically nirmatrelvir–ritonavir — following claims many patients were being “short-changed” and left unprotected. Federal…
COVID-19 antiviral still effective against Omicron, real-world studies show
Nirmatrelvir–ritonavir halves the risk of death and hospitalisation in patients with mild COVID-19 at risk of severe disease — even during the Omicron variant era…
A new COVID-19 antiviral is on the horizon, but how does it fare?
A new oral antiviral might be more favourable than nirmatrelvir–ritonavir in shortening recovery times for at-risk adults with COVID-19, a study suggests. The China-based phase…
Remdesivir reduces COVID-19 hospitalisation or death by 84%
Findings challenge the drug’s controversial past
Molnupiravir still aids recovery from COVID-19: University of Oxford trial
Molnupiravir speeds up recovery in high-risk patients with COVID-19 but has no effect on death or hospitalisations compared with usual care, confirm the long-awaited results…
Don’t rule out molnupiravir just yet, says RACGP
The RACGP is urging GPs to use their own clinical judgement when prescribing COVID-19 antivirals, following mixed messages regarding the appropriate use of molnupiravir. Last…
Is Professor Michael Kidd contradicting the national expert taskforce on prescribing molnupiravir?
This week a media storm burst after one of Australia’s top health officials issued a statement on the COVID-19 antiviral molnupiravir. The official turned out to be former RACGP…
Doctors told not to routinely prescribe molnupiravir for mild COVID-19
GPs are being advised against the routine use of molnupiravir to treat patients with mild COVID-19 following evidence the antiviral failed to reduce deaths or…
‘Last resort’ COVID-19 treatment outperforms molnupiravir in trial
A leading infectious diseases expert has urged health authorities to rethink their stance on the COVID-19 treatment sotrovimab, with new evidence suggesting it may outperform…
